共 1664 条
[21]
Chow LQM(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2521-2532
[22]
Vokes EE(2020)Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials Ann Oncol: Off J Eur Soc Med Oncol 31 50-60
[23]
Felip E(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma New Engl J Med 352 987-996
[24]
Holgado E(2019)Multiple high-grade gliomas: epidemiology, management, and outcome: a systematic review and meta-analysis Neurosurg Rev 42 263-275
[25]
Barlesi F(2009)FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme Oncologist 14 1131-1138
[26]
Kohlhaeufl M(2015)Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143 J Clin Oncol 33 3010-3010
[27]
Rodriguez O(2018)Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 Neuro Oncol 20 674-686
[28]
Burgio MA(2014)Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy Int J Cancer 134 2437-2447
[29]
Fayette J(2010)Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J Clin Oncol: Off J Am Soc Clin Oncol 28 4722-4729
[30]
Gettinger SN(2015)A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study Neuro Oncol 17 854-861